The clinical-stage biopharmaceutical company saw the highest jump in retail interest after reporting positive topline data ...

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

SWTX's desmoid tumor drug, Ogsiveo, is driving its top line. The recent FDA nod for Gomekli to treat a rare tumor diversifies its commercial portfolio.

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

Our analysis of options history for SpringWorks Therapeutics SWTX revealed 9 unusual trades. Delving into the details, we ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Barclays analyst Peter Lawson says SpringWorks Therapeutics (SWTX) this morning cancelled from the firm’s conference next week, following ...

Ogsiveo's net product revenues were $172 million in 2024. Last month, the FDA approved SpringWorks’ MEK inhibitor, Gomekli (mirdametinib) for the treatment of adult and pediatric patients 2 ...

Oppenheimer Asset Management Inc. lessened its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 6.2% in ...

On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...